Prescription Privacy
DEA vs. ACLU

You have "no constitutionally protected privacy interest" in your prescription records, according to the Drug Enforcement Administration (DEA). In an August brief before an Oregon U.S. District Court, the federal agency defended its practice of obtaining personal medical information without a warrant.
The American Civil Liberties Union (ACLU) is representing four patients and a doctor who object to the DEA's acquisition of their records via Oregon's Prescription Drug Monitoring Program, a public health database aimed at helping doctors detect and avoid drug abuse and overdoses. The plaintiffs argue that the DEA should not be allowed unfettered access to confidential medical information, such as prescriptions for anxiety meds and sex-change hormones.
In a September blog post about the case, ACLU staff attorney Nathan Wessler argued that the "third party doctrine"-which holds that citizens relinquish privacy rights when they give information to a company or other entity-ought not apply in this case. "Telling your doctor that you have an anxiety disorder or HIV," Wessler wrote, "is nothing like letting the power company read your electricity meter. "
Editor's Note: As of February 29, 2024, commenting privileges on reason.com posts are limited to Reason Plus subscribers. Past commenters are grandfathered in for a temporary period. Subscribe here to preserve your ability to comment. Your Reason Plus subscription also gives you an ad-free version of reason.com, along with full access to the digital edition and archives of Reason magazine. We request that comments be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of reason.com or Reason Foundation. We reserve the right to delete any comment and ban commenters for any reason at any time. Comments may only be edited within 5 minutes of posting. Report abuses.
Please
to post comments
Emergency Management Agency, which is responsible
brief before an Oregon U.S. District Court, the federal agency defended its practice of